Confluence Life Sciences Inc. is building a library of chemical probes that interact with cysteine-containing active sites of certain kinases, which could allow for quicker and more efficient discovery of inhibitors of difficult targets.

A lead molecule against MAP kinase kinase kinase 7 (MAP3K7; TAK1) is expected to begin Phase I testing in late 2014.